Development of Long-circulating Lapachol Nanoparticles: Formation, Characterization, Pharmacokinetics, Distribution and Cytotoxicity

Overview

Journal RSC Adv

Publisher Royal Society of Chemistry

Specialty Chemistry

Date 2022 May 6

PMID 35518271

Authors

Qunying Chen

Lu Bai

Xuelin Zhou

Pingxiang Xu

Xiaorong Li

Huanli Xu

Yuanyuan Zheng

Yuming Zhao

Shousi Lu

Ming Xue

Affiliations

Soon will be listed here.

Abstract

Lapachol is an active compound for the treatment of malignant brain glioma. However, its physicochemical properties limit its clinical application. The purpose of this study is to develop a nano-drug delivery system (LPC-LP) loaded with lapachol (LPC), which remarkably prolongs the half-life in the body, and increases the brain intake, therefore, achieving a better anticancer effect in the treatment of glioma. In order to optimize the formulation of liposomes, an orthogonal design was adopted with entrapment efficiency (EE) as the index. The characterization of the optimized formulation was evaluated . To assess the safety profile and effect of LPC-LP, a rapid and sensitive ultra-fast liquid chromatography with tandem mass spectrometry (UPLC-MS/MS) method was developed for studying the pharmacokinetics and brain distribution of LPC-LP and LPC. Finally, the cytotoxicity of the two preparations on C6 cells was studied by the MTT assay. The results showed that the average particle size of LPC-LP was 85.92 ± 2.35 nm, the EE of liposomes was 92.52 ± 1.81%, and the charge potential was -40.70 ± 9.20 mV. An release study showed that the release of lapachol from LPC-LP was delayed compared to LPC, indicating that LPC-LP was a sustained and controlled release system. The UPLC-MS/MS method was fully validated in both plasma and brain tissue according to the Food and Drug Administration (FDA) recommended guidelines, and successfully used for quantification of lapachol . After intravenous administration, LPC-LP prolonged circulation time of lapachol in the body and increased brain intake. Besides, the MTT results revealed that the IC value of LPC-LP on C6 cells significantly decreased, compared with LPC, which further confirmed that LPC-LP enhanced the inhibition of C6 cells and improved the anti-glioma effect. In conclusion, LPC-LP could serve as a promising candidate for the clinical application of lapachol in the treatment of glioma.

Citing Articles

Determination of Photosensitizing Potential of Lapachol for Photodynamic Inactivation of Bacteria.

Lima R, Flores R, Miessi G, Pulcherio J, Aguilera L, Araujo L Molecules. 2024; 29(21).

PMID: 39519826 PMC: 11547567. DOI: 10.3390/molecules29215184.

Long-Circulating and Brain-Targeted Liposomes Loaded with Isoliquiritigenin: Formation, Characterization, Pharmacokinetics, and Distribution.

Song W, Bai L, Xu P, Zhao Y, Zhou X, Xiong J Pharmaceutics. 2024; 16(8).

PMID: 39204320 PMC: 11359040. DOI: 10.3390/pharmaceutics16080975.

How Should the Worldwide Knowledge of Traditional Cancer Healing Be Integrated with Herbs and Mushrooms into Modern Molecular Pharmacology?.

Kirdeeva Y, Fedorova O, Daks A, Barlev N, Shuvalov O Pharmaceuticals (Basel). 2022; 15(7).

PMID: 35890166 PMC: 9320176. DOI: 10.3390/ph15070868.

Nucleoside transporter-guided cytarabine-conjugated liposomes for intracellular methotrexate delivery and cooperative choriocarcinoma therapy.

Fei W, Zhao Y, Wu X, Sun D, Yao Y, Wang F J Nanobiotechnology. 2021; 19(1):184.

PMID: 34130695 PMC: 8207694. DOI: 10.1186/s12951-021-00931-3.

References

Zhang X, Zhao M, Cao N, Qin W, Zhao M, Wu J . Construction of a tumor microenvironment pH-responsive cleavable PEGylated hyaluronic acid nano-drug delivery system for colorectal cancer treatment. Biomater Sci. 2020; 8(7):1885-1896. DOI: 10.1039/c9bm01927h. View

Song X, Liu S, Jiang Y, Gu L, Xiao Y, Wang X . Targeting vincristine plus tetrandrine liposomes modified with DSPE-PEG-transferrin in treatment of brain glioma. Eur J Pharm Sci. 2016; 96:129-140. DOI: 10.1016/j.ejps.2016.09.024. View

Esteves-Souza A, Figueiredo D, Esteves A, Camara C, Vargas M, Pinto A . Cytotoxic and DNA-topoisomerase effects of lapachol amine derivatives and interactions with DNA. Braz J Med Biol Res. 2007; 40(10):1399-402. DOI: 10.1590/s0100-879x2006005000159. View

Kuo Y, Wang L, Rajesh R . Targeting human brain cancer stem cells by curcumin-loaded nanoparticles grafted with anti-aldehyde dehydrogenase and sialic acid: Colocalization of ALDH and CD44. Mater Sci Eng C Mater Biol Appl. 2019; 102:362-372. DOI: 10.1016/j.msec.2019.04.065. View

Wei L, Guo X, Yang T, Yu M, Chen D, Wang J . Brain tumor-targeted therapy by systemic delivery of siRNA with Transferrin receptor-mediated core-shell nanoparticles. Int J Pharm. 2016; 510(1):394-405. DOI: 10.1016/j.ijpharm.2016.06.127. View

Owens 3rd D, Peppas N . Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2005; 307(1):93-102. DOI: 10.1016/j.ijpharm.2005.10.010. View

Gai X, Cheng L, Li T, Liu D, Wang Y, Wang T . In vitro and In vivo Studies on a Novel Bioadhesive Colloidal System: Cationic Liposomes of Ibuprofen. AAPS PharmSciTech. 2017; 19(2):700-709. DOI: 10.1208/s12249-017-0872-4. View

Vardhan H, Mittal P, Adena S, Upadhyay M, Mishra B . Development of long-circulating docetaxel loaded poly (3-hydroxybutyrate-co-3-hydroxyvalerate) nanoparticles: Optimization, pharmacokinetic, cytotoxicity and in vivo assessments. Int J Biol Macromol. 2017; 103:791-801. DOI: 10.1016/j.ijbiomac.2017.05.125. View

Zhu J, Zhang W, Wang D, Li S, Wu W . Preparation and characterization of norcantharidin liposomes modified with stearyl glycyrrhetinate. Exp Ther Med. 2018; 16(3):1639-1646. PMC: 6122258. DOI: 10.3892/etm.2018.6416. View

10.

Yang C, Zhang M, Merlin D . Advances in Plant-derived Edible Nanoparticle-based lipid Nano-drug Delivery Systems as Therapeutic Nanomedicines. J Mater Chem B. 2018; 6(9):1312-1321. PMC: 6053076. DOI: 10.1039/C7TB03207B. View

11.

Sanoff H, Moon D, Moore D, Boles J, Bui C, Blackstock W . Phase I/II trial of nano-camptothecin CRLX101 with capecitabine and radiotherapy as neoadjuvant treatment for locally advanced rectal cancer. Nanomedicine. 2019; 18:189-195. PMC: 7881832. DOI: 10.1016/j.nano.2019.02.021. View

12.

Siegel R, Ward E, Brawley O, Jemal A . Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61(4):212-36. DOI: 10.3322/caac.20121. View

13.

Fiorito S, Epifano F, Bruyere C, Mathieu V, Kiss R, Genovese S . Growth inhibitory activity for cancer cell lines of lapachol and its natural and semi-synthetic derivatives. Bioorg Med Chem Lett. 2013; 24(2):454-7. DOI: 10.1016/j.bmcl.2013.12.049. View

14.

Xu H, Chen Q, Wang H, Xu P, Yuan R, Li X . Inhibitory effects of lapachol on rat C6 glioma in vitro and in vivo by targeting DNA topoisomerase I and topoisomerase II. J Exp Clin Cancer Res. 2016; 35(1):178. PMC: 5112657. DOI: 10.1186/s13046-016-0455-3. View

15.

Dwivedi P, Khatik R, Khandelwal K, Taneja I, Raju K, Wahajuddin . Pharmacokinetics study of arteether loaded solid lipid nanoparticles: an improved oral bioavailability in rats. Int J Pharm. 2014; 466(1-2):321-7. DOI: 10.1016/j.ijpharm.2014.03.036. View

16.

Gratton S, Ropp P, Pohlhaus P, Luft J, Madden V, Napier M . The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci U S A. 2008; 105(33):11613-8. PMC: 2575324. DOI: 10.1073/pnas.0801763105. View

17.

Venditto V, Szoka Jr F . Cancer nanomedicines: so many papers and so few drugs!. Adv Drug Deliv Rev. 2012; 65(1):80-8. PMC: 3565003. DOI: 10.1016/j.addr.2012.09.038. View

18.

Song X, Han X, Yu F, Zhang X, Chen L, Lv C . Polyamine-Targeting Gefitinib Prodrug and its Near-Infrared Fluorescent Theranostic Derivative for Monitoring Drug Delivery and Lung Cancer Therapy. Theranostics. 2018; 8(8):2217-2228. PMC: 5928882. DOI: 10.7150/thno.24041. View

19.

Thakor A, Gambhir S . Nanooncology: the future of cancer diagnosis and therapy. CA Cancer J Clin. 2013; 63(6):395-418. DOI: 10.3322/caac.21199. View

20.

Hu Y, Rip J, Gaillard P, de Lange E, Hammarlund-Udenaes M . The Impact of Liposomal Formulations on the Release and Brain Delivery of Methotrexate: An In Vivo Microdialysis Study. J Pharm Sci. 2017; 106(9):2606-2613. DOI: 10.1016/j.xphs.2017.03.009. View